June 06, 2021
A study from the 2021 ASCO Annual Meeting examined the effect that oral anticancer agent initiation may have on adherence rates in patients with multiple myeloma and chronic conditions.
A study from the 2021 ASCO Annual Meeting assessed the prevalence of oncology drug shortages and how they hinder care for patients with cancer.
June 05, 2021
A poster presentation at the 2021 ASCO Annual Meeting discussed survival trends among patients with chronic lymphocytic leukemia.
A community oncology practice implemented a team-based approach to utilizing biosimilars.
June 04, 2021
Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.
A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.
Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.
Findings from the phase 3 RELATIVITY-047 trial were presented at the 2021 ASCO Annual Meeting.
June 08, 2020
The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.
June 03, 2020
The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.
